Investor News

Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research Organisation

Oxford Vacmedix appoints Shanghai based PharmaLegacy to carry out the proof of concept work of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that PharmaLegacy of Shanghai, China has been appointed to complete the proof …

Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research OrganisationRead More »

Oxford Vacmedix completes Series A financing

Oxford Vacmedix UK Limited (OVM) has completed its Series A financing round of $12.5m (£9m). Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors, including Cancer ROP, a leading …

Oxford Vacmedix completes Series A financingRead More »